Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
- MHLW Council Deems Public Knowledge-Based Filings Acceptable for 8 Fertility Treatment Indications
January 28, 2022
- MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
- Japan Panel Agrees to Vaccinate Children under Free COVID-19 Inoculation Program
January 27, 2022
- Up to 3 Refills Permitted per Prescription, No Refilling for Drugs with Dosage Restrictions: Chuikyo
January 27, 2022
- Drug Pricing Rules to Be Applied to BMS’ CAR-T Therapy Abecma: Chuikyo
January 27, 2022
- PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive
January 25, 2022
- Lagevrio Should Not Be Given to Asymptomatic COVID Patients: MHLW
January 25, 2022
- Japan to Import Pfizer’s Pediatric Vaccine Next Month, Inoculations to Begin in March: Minister
January 25, 2022
- MHLW Panel Backs Wholesaler Data Use to Monitor Vaccine Shortages in Public Programs
January 25, 2022
- Providing Info on Investigational Drugs on Company Websites Violates PMD Law: MHLW
January 25, 2022
- Lilly’s Retevmo Up for PAFSC Review for Thyroid Cancer on Feb. 4; Lenvima-Keytruda Combo on Agenda for RCC
January 24, 2022
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Promote Both Pfizer/Moderna Vaccines for Boosters: Health Minister
January 24, 2022
- Veklury Allowed for Administration in Homebound Patients
January 24, 2022
- JPMA Calls for Data Consolidation under Medical Infrastructure Law: Govt Hearing
January 24, 2022
- MHLW Approves Lilly’s Migrane Drug Reyvow, Amgen’s KRAS Inhibitor and More
January 21, 2022
- Pfizer’s Comirnaty Bags Japan Approval for Ages 5-11; Actemra OK’ed for COVID-19
January 21, 2022
- Govt Panel Compiles Draft Proposal for Bill to Bolster Supply Chains for Drugs, Essential Resources
January 21, 2022
- Pfizer’s Comirnaty Clears Key Panel for Ages 5-11; Actemra Set for COVID-19 Nod
January 21, 2022
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…